Compared with DPP4‐inhibitor initiators, patients starting low‐affinity and high‐affinity sulfonylureas had generally comparable baseline characteristics but were more often enrolled in the first two calendar years of the study, had lower aDSCI scores, less often received insulin, or had a slightly lower prevalence of certain cardiovascular disease histories (the differences <3%), including MI and heart failure. Here, INS is linked to cardiovascular disorder.